HMGB1 and cancer: Single agent chemotherapy treatment did not significantly upregulate HMGB1 on OGJ cells, however, their combination as part of the FLOT and CROSS CT regimen did, further supporting a rationale for combining different chemotherapies with distinct mechanisms of action to not only reduce the development of chemoresistance via cancer cell intrinsic genetic mutations but also due to their ability to increase immunogenic cell death in combination.